Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARTNERSHIP DISCUSSIONS FOR PILAVAPADIN REMAIN UNDERWAY FOLLOWING PHASE 2B PROGRESS STUDY RESULTS IND-ENABLING STUDIES OF LX9851 FOR OBESITY AND RELATED DISORDERS ON TRACK FOR COMPLETION IN 2025 WITH LICENSEE NOVO NORDISK EXPECTED TO SUBMIT IND ENROLLMENT COMPLETION FOR SONATA PHASE 3 STUDY IN BOTH OBSTRUCTIVE AND NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) ON TARGET FOR 2026 CONFERENCE CALL AND WEBCAST AT 8:30 AM ET  THE WOODLANDS, TEXAS, AUG. 06, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX), TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON KEY CORPORATE MILESTONES AND ACCOMPLISHMENTS. WE CONTINUE TO MAKE GREAT STRIDES AGAINST THE STRATEGY WE SET FORTH AS AN R&D FOCUSED COMPANY, SAID MIKE EXTON, PH.D.

LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

THE WOODLANDS, TEXAS, JULY 31, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT NASDAQ'S LISTING QUALIFICATIONS STAFF HAS DETERMINED THAT THE CLOSING BID PRICE OF THE COMPANY'S COMMON STOCK HAS BEEN AT $1.00 PER SHARE OR GREATER FOR TEN CONSECUTIVE BUSINESS DAYS AND THAT, ACCORDINGLY, THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2). THIS UPDATE WAS PREVIOUSLY DISCLOSED IN THE COMPANY'S CURRENT REPORT ON FORM 8-K FILED ON JULY 28, 2025.

LEXICON PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

THE WOODLANDS, TEXAS, JULY 23, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 6, 2025, PRIOR TO MARKET OPEN. MANAGEMENT WILL CONDUCT A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET (7:30 A.M. CT) THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND TO PROVIDE A BUSINESS UPDATE.

LEXICON PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

PATIENT INSIGHTS INFORMED THE DEVELOPMENT OF PILAVAPADIN, LEXICON'S INVESTIGATIONAL, NOVEL, NON-OPIOID TREATMENT FOR PEOPLE SUFFERING FROM DPNP PATIENT INSIGHTS INFORMED THE DEVELOPMENT OF PILAVAPADIN, LEXICON'S INVESTIGATIONAL, NOVEL, NON-OPIOID TREATMENT FOR PEOPLE SUFFERING FROM DPNP

LEXICON TO PRESENT PATIENT-REPORTED DATA ON DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP) AT THE 7TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF PAIN AND NEUROSCIENCE (ASPN 2025)

ORAL PRESENTATION HIGHLIGHTED THE POST-HOC ANALYSIS DURING THE INTERVENTIONS TO PREVENT HYPOGLYCEMIA: BENCH TO BEDSIDE SESSION TREATMENT WITH SOTAGLIFLOZIN RESULTED IN NO INCREASED RISK AND A REDUCTION IN HYPOGLYCEMIA EVENTS, PARTICULARLY IN PATIENTS WITH BLOOD GLUCOSE 55 MG/DL THE WOODLANDS, TEXAS, JUNE 23, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) ANNOUNCED THAT A POST-HOC ANALYSIS OF CLINICAL STUDY DATA SHOWING A REDUCTION IN HYPOGLYCEMIC EVENTS WHEN SOTAGLIFLOZIN WAS ADDED TO OPTIMIZED INSULIN THERAPY FOR PEOPLE WITH TYPE 1 DIABETES (T1D) WAS PRESENTED YESTERDAY DURING THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA) IN CHICAGO, ILLINOIS. THE ADA EMPHASIZES THAT HYPOGLYCEMIA REMAINS AN IMPORTANT PATIENT MANAGEMENT ISSUE IN T1D.

DATA DEMONSTRATING SOTAGLIFLOZIN REDUCES THE RISK OF CLINICALLY IMPORTANT HYPOGLYCEMIC EVENTS IN ADULTS WITH TYPE 1 DIABETES WHEN ADDED TO INSULIN PRESENTED AT THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA)

THE WOODLANDS, TEXAS, JUNE 18, 2025 (GLOBE NEWSWIRE) --  LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT DATA FROM A STUDY EVALUATING THE IMPACT OF SOTAGLIFLOZIN ON HYPOGLYCEMIA IN PEOPLE WITH TYPE 1 DIABETES WILL BE DELIVERED AS AN ORAL PRESENTATION ON SUNDAY, JUNE 22, DURING THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA). AT THE MEETING, THE COMPANY WILL ALSO PRESENT TOPLINE DATA FROM ITS PROGRESS PHASE 2B STUDY EVALUATING PILAVAPADIN (LX9211) IN ADULTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN.

LEXICON TO PRESENT DATA AT THE 85TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION (ADA)

THE WOODLANDS, TEXAS, MAY 29, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN NEW YORK CITY ON THURSDAY, JUNE 5 AT 12:50 P.M. ET. THE LIVE EVENT AND A REPLAY OF THE PRESENTATION CAN BE ACCESSED VIA THE EVENTS PAGE OF THE COMPANY'S WEBSITE AT HTTPS://INVESTORS.LEXPHARMA.COM/.

LEXICON PHARMACEUTICALS TO PRESENT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

LEXICON IS EVALUATING THE SAFETY AND EFFICACY OF SOTAGLIFLOZIN IN PATIENTS WITH BOTH OBSTRUCTIVE AND NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) PIVOTAL PHASE 3 CLINICAL TRIAL IS ACTIVELY ENROLLING PATIENTS IN 20 COUNTRIES, WITH ALL SITES EXPECTED TO BE OPERATIONAL BY Q3 2025 THE WOODLANDS, TEXAS, MAY 19, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED DETAILS OF ITS  SO TAGLIFLOZI N IN PATIENTS WITH SYMPTOM AT IC OBSTRUCTIVE A ND NON-OBSTRUCTIVE H YPERTROPHIC C ARDIO M YOPATHY (SONATA-HCM) STUDY WERE PRESENTED ON SATURDAY, MAY 17. THE STUDY DESIGN WAS DISCLOSED IN BELGRADE, SERBIA AT ONE OF THE PREMIER INTERNATIONAL HEART FAILURE MEETINGS: HEART FAILURE 2025, THE ANNUAL CONGRESS OF THE HEART FAILURE ASSOCIATION OF THE EUROPEAN SOCIETY OF CARDIOLOGY.

SONATA-HCM STUDY DESIGN PRESENTED AT HEART FAILURE 2025, THE ANNUAL CONGRESS OF THE HEART FAILURE ASSOCIATION OF THE EUROPEAN SOCIETY OF CARDIOLOGY

COMPANY HAD A STRONG START TO 2025, EMERGING AS AN R&D-FOCUSED ORGANIZATION EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851 EXECUTED; IND-ENABLING STUDIES ON TRACK FOR COMPLETION IN 2025 PHASE 2B PROGRESS STUDY CONFIRMED 10 MG PILAVAPADIN AS APPROPRIATE DOSE FOR ADVANCEMENT INTO PHASE 3 DEVELOPMENT FOR DIABETIC PERIPHERAL NEUROPATHIC PAIN CONFERENCE CALL AND WEBCAST AT 5:00 PM ET THE WOODLANDS, TEXAS, MAY 13, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX), TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON KEY CORPORATE MILESTONES AND ACCOMPLISHMENTS. WE BEGAN 2025 DELIVERING ON THREE OF OUR GOALS FOR THIS YEAR, INCLUDING MOST RECENTLY AN EXCLUSIVE LICENSING AGREEMENT WITH NOVO NORDISK FOR LX9851 IN OBESITY AND RELATED DISORDERS, SAID MIKE EXTON, PH.D.

LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

THE WOODLANDS, TEXAS, MAY 06, 2025 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 3RD ANNUAL H.C. WAINWRIGHT BIOCONNECT INVESTOR CONFERENCE, TAKING PLACE AT THE NASDAQ WORLD HEADQUARTERS IN NEW YORK CITY, ON TUESDAY, MAY 20, AT 9:30 A.M. ET.

Lexicon Pharmaceuticals, Inc.

LXRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lexicon Pharmaceuticals, Inc.

LXRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LXRX